Meridian Bioscience subsidiary Bioline has introduced new EPIK miRNA panel assays worldwide, designed for miRNA profiling of cancer samples, biofluids and stem cells.
EPIK miRNA panel assays have been developed as part of a collaboration between Singapore’s MiRXES and Bioline.
By using a new approach developed by MiRXES, combinations of miRNA specific reverse transcriptase and hemi-nested real-time PCR primers were designed to maximise miRNA detection sensitivity and specificity.
Bioline president Marco Calzavara said: "The release of the EPIK miRNA panel assays follows the release of the ISOLATE II miRNA, Plant miRNA, Biofluids RNA, RNA/DNA/Protein and FFPE RNA/DNA Kits earlier this year and shows the continued commitment of Bioline to produce high quality miRNA kits to help researchers with miRNA expression profiling and quantification and in biomarker discovery."
PCR assays will deploy SensiSMART with SYBR Green to detect extremely low levels of miRNA with high specificity, helping to discriminate between closely related miRNA sequences.
This technology was validated independently by molecular diagnostic and pharmaceutical laboratories and showed superior performance to existing commercial assays.
The assays will allow researchers to quickly analyse miRNAs that suggest a correlation with the dysregulations in various cancers, in maintenance, differentiation and reprogramming of stem cells, in addition to look at circulating miRNAs that are regarded as a promising new class of biomarkers.
Meridian Life Science president Richard Eberly said: "We are excited about the release of the EPIK miRNA panel assays and the enhanced performance they provide for our important life science customers in the research, molecular diagnostic and pharmaceutical laboratories and biotechnology companies."
"We remain committed to the continued expansion of the rapidly growing portfolio of highly specialised molecular biology products from Bioline."
Meridian is focused on developing, manufacturing, marketing and distributing a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies.
By using a variety of methods, these products and diagnostic tests offer accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections.